The initial rationale for targeting B-RAF in cancer therapy was based on the premise that inhibiting its activity would downregulate the RAS/RAF/MEK/ERK signaling cascade, thereby suppressing tumor progression. This evidence concerns the gene RAF1 and neoplasm.